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Summary Mitotane is considered to be the drug of choice for patients with inoperable, recurrent and
metastatic adrenocortical carcinoma, although a favourable effect of this drug on survival has never been
documented. We evaluated the efficacy of mitotane treatment of 96 patients with adrenocortical carcinoma
followed up in our department between 1959 and 1992. Complete tumour resection was the goal of the initial
treatment. Mitotane treatment was classified according to serum trough concentrations on maintenance
therapy: low (<14mgl-') or high (>14mg1-'). Total tumour resection was feasible in 47 patients (49%),
and subtotal resection was performed in 37 patients (39%). Patients who underwent total tumour resection
survived significantly longer than those who did not (P<0.001). Adjuvant mitotane therapy (n = 11) did not
influence survival after total resection. Sixty-two patients were given mitotane treatment at some time during
their illness, only 30 of whom reached high maintenance serum levels. Mitotane treatment with high serum
levels had an independently favourable influence on patient survival, using univariate (P<0.01) and mul-
tivariate analysis (P = 0.01). Mitotane treatment resulting in low serum levels was tantamount to not giving
mitotane at all. We conclude that mitotane treatment in adrenocortical carcinoma is effective only when high
serum levels can be achieved.
Carcinoma of the adrenal cortex carries a poor prognosis
(Macfarlane, 1958; Hutter & Kayhoe, 1966a; Venkatesh et
al., 1989; Luton et al., 1990). According to recently reported
clinical studies, only 20-25% of patients survive for more
than 5 years after the diagnosis is made (Venkatesh et al.,
1989; Luton et al., 1990). Early diagnosis and radical surgery
offer the best hope for long-term survival. However, the
diagnosis is frequently delayed and often only made at an
advanced stage because of its rarity and the deep retro-
peritoneal localisation of the adrenal glands.
Another important factor contributing to the prognosis is
the poor response to chemotherapeutic agents. Mitotane
(o,p'-DDD) is considered to be the drug of choice for
patients with inoperable, recurrent and metastatic disease
(Samaan & Hickey, 1987). Increase in survival (Hutter &
Kayhoe, 1966b; Lubitz et al., 1973; Venkatesh et al., 1989)
and even long-term remission and cure of adrenocortical
cancer (Becker & Schumacher, 1975; Jarabak & Rice, 1981)
have been attributed to mitotane. Unfortunately, because of
the rarity of the tumour, no randomised or controlled studies
have been performed to assess mitotane's effect on patients'
survival in adrenocortical carcinoma. However, a recently
completed retrospective (multivariate) analysis of 105
patients with carcinoma of the adrenal cortex failed to docu-
ment improved survival due to mitotane therapy (Luton et
al., 1990). In a retrospective study conducted in our hospital
(van Slooten et al., 1984) an improved survival was
documented in 14 patients receiving mitotane therapy, when
serum levels exceeded 14 mg 1-.
The objective of this study was to evaluate the relevance of
mitotane serum levels greater than 14mgl1' in relation to
other factors of possible beneficial influence on patient sur-
vival, in our extended series of 96 patients.
Patients and methods
Patients
Ninety-six patients with adrenocortical carcinoma were
evaluated and followed up in the Department of Endocrin-
ology of the University Hospital of Leiden from, 1959 to
1991. Follow-up for this report was closed on 1 January
1992. Patients underwent clinical, radiological and hormonal
assessments. The 42 patients described in the series of van
Slooten et al. (1984) are included in this report.
Definitions
Clinical hormonal activity, assessed at the time of diagnosis,
was considered to be present when medical history and
physical examination were compatible with a diagnosis of
Cushing's syndrome, Conn's syndrome, virilisation or
feminisation.
Staging was based on clinical data and radiological studies
at the time of diagnosis. Radiological assessments of the
primary tumour were initially made with intravenous pyelo-
gram and/or arteriography. Later patients were investigated
with ultrasound, computerised tomography (CT) and some
of them with magnetic resonance imaging (MRI). The
radiological detection of metastases in the later patients
could be done more reliably with ultrasound, CT or MRI
scanning. Operative findings and pathological examination
were included in the staging procedure. Local disease was
defined as disease confined to the adrenal gland. Metastatic
disease was defined as disease macroscopically extending
beyond the limits of the adrenal gland into surrounding
organs and tissues, or when distant metastases were present.
Metastases becoming manifest within 3 months of surgery for
the primary tumour were considered to be present at the time
of surgery. Surgical resection of the tumour was considered
total when local disease could be completely resected. In the
case of post-operative macroscopically or microscopically
residual tumour tissue, or in the case of metastatic disease,
tumour resection was considered subtotal.
Evaluation of tumour response was based on the standard
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criteria of complete remission (no detectable disease), partial
response (> 50% reduction in tumour mass for more than 1
month), stable disease and progressive disease (>25%
tumour increase). Survival periods were calculated from the
time of diagnosis to the time of death.
Treatment
Surgery Surgical excision of the primary tumour was
always performed when the patients' clinical condition per-
mitted it. Complete resection, metastases included, was the
goal of surgery. When complete resection was not possible,
maximal debulking of tumour load was pursued. Recurrent
tumours were resected or debulked whenever possible.
Mitotane Mitotane therapy was started with 4-8 g per day
given in four equal doses. In order to maximise intestinal
absorption of the drug, treatment was started with mitotane
given in chocolate, milkpowder or oil emulsion preparations
(Moolenaar et al., 1981). Maintenance therapy was continued
in the form of tablets (Calbiochem or Bristol-Myers).
Mitotane serum concentrations were determined according to
the method described by Moolenaar et al. (1977). Blood for
mitotane estimation was drawn at least 12 h after the last
dose was taken. During treatment, serum levels were
measured at least once a month. Maintenance serum levels
were classified as low (<14mgl-') or high (> 14mgl1').
The cut-off point was based on the empirical findings,
reported by van Slooten et al. (1984), that seven of eight
patients with tumour regression had mitotane serum levels
above 14 mg 1', whereas 19 of 20 patients without an objec-
tive tumour regression had mitotane serum levels lower than
14 mg I'. Because of these findings, after 1981 a standard
target mitotane serum trough level above 14 mg I`, and
when possible over 20 mg I1, was aimed for. Mitotane
therapy was continued for 2 years if resection was judged to
be complete or for 1 year after apparent disappearance of the
tumour. In addition to mitotane, all patients received hydro-
cortisone (30-120 mg day-') or fludrocortisone acetate
(0.1-0.4 mg day-'). Steroid replacement therapy started at
the same time as the start of mitotane therapy when there
was no, or only mild, clinical hormonal syndrome. In the
case of an overt hormonal syndrome, steroid replacement
was instituted when adrenal insufficiency became manifest, or
was expected to occur. When necessary, the patients were
treated with metoclopramide and loperamide to alleviate gas-
trointestinal side-effects.
Other chemotherapy Administration of other chemothera-
peutic agents in addition to mitotane was considered in the
presence of clinical and biochemical progression of
adrenocortical carcinoma. In addition, chemotherapy was
considered when a patient refused mitotane therapy or as
judged by the attending physician. The CAP regimen (cyclo-
phosphamide, doxorubicin and cisplatin) (van Slooten &
Oosterom, 1983) was one of the therapeutic options. Strepto-
zotocin (Erikson et al., 1987) or cisplatin and etoposide
(Johnson & Greco, 1986) were alternative therapies.
Statistical analysis
Survival curves were calculated by the Kaplan-Meier method.
The Lee-Desu statistic test was used for comparison of
survival curves. A multivariate analysis according to the Cox
proportional hazards model was performed to evaluate the
independent effect of several factors on patient survival (see
Results section) (Mathews & Farewell, 1985).
Results
Clinical characteristics (Table I)
The mean age of the patients at diagnosis was 44.4 years (s.d.
16.5 years). There were 56 female and 40 male patients. The
left adrenal gland was involved in 51 (53%) patients and the
right in 45 (47%) patients. Involvement was strictly
unilateral.
Clinical hormonal syndromes were present in 39 (69%) of
the female and 18 (45%) of the male patients. Thirty-nine
patients (12 male and 27 female) had Cushing's syndrome
and four patients had Conn's syndrome. Virilisation was
present in one prepubertal boy and in 11 women; feminisa-
tion was observed in two men. At presentation, 22 men and
17 women demonstrated no abnormal endocrine features.
Pain was the major non-endocrine symptom, and was
documented in 45 (47%) of patients. A palpable abdominal
mass was present in 28 (29%) patients.
Metastases were present in 38 patients at diagnosis. The
liver was the most frequently affected site (26 patients), with
the lungs being next in frequency (15 patients).
Treatment
A flow chart of treatment is shown in Figure 1.
Surgery Eighty-four patients underwent surgery. Total
tumour resection was possible in 47 patients. In eight of these
patients the tumour capsule had ruptured during surgery. In
Table I Clinical details of 96 patients with adrenocortical carcinoma at the
time of diagnosis
Total Women Men
(n = 96) (n = 56) (n = 40)
Age (years)
Mean (s.d.) 44.4 (16.5) 43.3 (16.4) 45.9 (16.7)
Range 1-78 1-71 7-78
Tumour localisation
Left gland 51 28 23
Right gland 45 28 17
Clinical manifestations
Hormonal 57 39 18
Cushing 39 27 12
Virilisation 12 11 1
Feminisation 2 0 2
Conn 4 1 3
Non-hormonal 39 17 22
Other signs/symptoms
Pain 45 24 21
Abdominal mass 28 17 22
Metastases 38 21 17ADRENOCORTICAL CANCER AND MITOTANE TREATMENT 949
Patients Srca 2 Mitotane cheotherap resection :: ceohrp
No 15 2
...........- Low 17 1
Total 47 High 15 4
Local 58 Subtota 11 No 12 3
..~E+~3~ Low 11 2
Metastasized 38 Subtotal 26 High 14 6
No 12 N No 7 3
LLow 4 _0
High 1 0
Total1 47 No 34
Totals 96 Subtotal 37 Low 32
No 12 High 30
Figure 1 Flow chart of treatment in 96 patients with adrenocortical carcinoma. Eighty-four patients underwent surgery; in 47 of
these patients a total tumour resection was possible. Sixty-two patients were treated with mitotane at some time during their illness.
Thirty of these patients achieved high serum levels of the drug during maintenance therapy. Other chemotherapy was given to 21
patients. aNo = no mitotane therapy; low = serum levels <14 mg 1-'; high = serum levels > 14 mgI-'.
37 patients the tumour could not be resected completely.
Twelve patients were judged to be inoperable.
Survival of patients with total tumour resection was
significantly better than survival of patients undergoing only
a subtotal tumour resection (P<0.001) (Figure 2). Five year
survival after total resection was 49%, and after subtotal
resection only 9%. Rupture of the tumour capsule during
resection did not significantly influence survival (P= 0.38).
All patients with inoperable disease died within 18 months of
diagnosis.
Mitotane Sixty-two patients received mitotane at some time
during their illness between 1965 and 1991. The five patients
diagnosed between 1959 and 1965 and not treated with
mitotane had local disease. Maintenance therapy serum levels
were found to be high (range 14-50 mg I-', 74% between 14
and 25mgl1) in 30 patients and low (range 4-13mgl',
84% between 7 and 11 mg -') in 32 others. The mitotane
formulations from the two manufacturers were bioequivalent.
No differences between serum levels reached depending on
the brand used were observed.
Forty of the 62 patients who were treated with mitotane at
some time during their illness received the drug early in the
course of their illness. Twenty-nine of these 40 patients had
measurable tumour size because they were not operated upon
(five patients) or because they only underwent a subtotal
resection (24 patients). A tumour response was only seen in
six patients having high maintenance mitotane serum levels
(Table II) (P<0.001, chi-square test). In three patients, a
partial tumour response and in another three patients a
complete remission lasting five, 69 and 190 (ongoing) months
was observed. The high mitotane level group survival was
significantly longer than that of the low-level group
(P<0.001) (Figure 3).
One patient with a mitotane serum level less than
14 mg 1-', and who was reported in the original series of van
Slooten et al. (1984) to have a tumour response, did not meet
the stricter criteria of WHO and set for the present study.
Mitotane therapy was given to 26 of the 38 patients who
had a tumour recurrence. Four patients had also received a
first course of mitotane treatment. Tumour response was
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Figure 2 Actuarial survival rates from time of diagnosis in 96
patients with adrenocortical carcinoma according to surgery.
Total (T) = total tumour resection; subtotal (S) = subtotal
tumour resection; no (N) = no tumour resection. T vs S,
P<0.001; T vs N, P<0.001; S vs N, P=0.05.
again only observed in patients with a high maintenance
mitotane level (n = 9) (Table III) (P<0.001, chi-square test).
Five of these patients had a complete remission lasting for
2-120 months at the time of reporting.
Mitotane therapy was given to 11 patients after apparently
complete tumour resection. Six of these patients reached
mitotane serum levels over 14 mg 1-'. Median survival of the
11 patients treated with adjuvant mitotane was 51 months.
The median survival of the patients with complete tumour
resection without adjuvant therapy was 61 months. The
differences in survival and disease-free survival between these
groups of patients were not significant.
Mitotane side-effects The main side-effects of mitotane were
anorexia, nausea, vomiting, diarrhoea and CNS toxicity.
Mitotane treatment had to be discontinued in ten patients
because of side-effects. These were anorexia and nausea in
eight patients and neuropsychiatric symptoms in two
patients. Nine of the ten patients stopping treatment because
of side-effects never achieved high mitotane serum levels.
0950 H.R. HAAK et al.
H vs L: p<0.001|
75-
> 50
cn ~~~~~High(n= 14)
25
Low (n = 15)
0 12 24 36 48 60 72 84 96
Months
Figure 3 Actuarial survival rates from time of diagnosis in 29
patients with evaluable tumour (no operation, n = 5; subtotal
operation, n = 24) according to serum levels of mitotane
(mitotane therapy given early in the course of their disease). High
(H) = serum levels > 14mg -'; low (L) = serum levels
<14mgl-'. H vs L, P<0.001.
Table II Responsea of the primary tumour to mitotane therapy in
relation to mitotane serum levels (n = 29)
<14mgtV' J14mgh-'
Response 0 6
No response 15 8
P = 0.004 (chi-square test). aResponse includes complete remission
and partial response.
Table III Responsea of recurrent tumour to mitotane therapy in
relation to mitotane serum levels (n = 23)
<14mgl-' >14mgl'
Response 0 9
No response 10 4
P = 0.0008 (chi-square test). aResponse includes complete remis-
sion and partial response.
Gastrointestinal manifestations were present early in the
course of treatment but in most patients could be controlled
well enough not to require discontinuation of the drug.
Mitotane serum levels associated with the gastrointestinal
side-effects were all above 5 mg 1'. CNS toxicity was seen
especially with high mitotane serum levels, with cerebellar
ataxia being the most common manifestation. Neuropsycho-
logical impairment was found during therapy. Deterioration
varied individually from mild to severe, but always occurred
when mitotane serum level exceeded 15 mg 1-. CNS toxicity
reversed completely after drug withdrawal. A prolonged
bleeding time was encountered in 90% of patients tested for
platelet function (n = 10). Less frequent side-effects observed
were rash (2-6 weeks after starting therapy) and a mild
leucopenia.
Other therapy Twenty-one patients received one or two
different chemotherapeutic regimens, apart from mitotane, at
some time during their illness. Ten patients were treated early
in the course of the disease and 11 during recurrence of the
disease. The CAP regimen was administered to 12 patients, in
two patients after unsuccessful mitotane treatment. Two
patients achieved partial remissions lasting 18 and 23
months.
Seven patients received streptozotocin after tumour pro-
gression under mitotane, all without objective tumour re-
sponse. Three patients received the cisplatin-etoposide
regimen without tumour response.
Multivariate analysis ofsurvival Using the Cox proportional
hazards model, we evaluated the influence of the following
variables on patient survival: (a) outcome of first surgery (no
resection, subtotal or total resection); (b) mitotane treatment
at some time during illness (no mitotane, low and high
mitotane levels); (c) other chemotherapy at some time during
illness (no, yes); (d) age at diagnosis (<40 years, >40 years);
(e) year of diagnosis (<1980, > 1980); (f) sex (male, female);
and (g) clinical features of hormonal dysfunction at presenta-
tion (no, yes). In all patients stepwise analysis of these
variables showed that total resection at first surgery
(P<0.001), mitotane treatment at some time during illness
with high serum levels (P = 0.01) and female sex (P = 0.03)
had independently a favourable influence on cumulative sur-
vival.
Stepwise analysis on the 49 patients who could not be
operated upon (n = 12) or who had a subtotal tumour resec-
tion (n = 37) showed an independent, favourable influence on
survival when mitotane treatment given at some time during
illness resulted in high maintenance serum levels (P<0.001)
and when treatment with other chemotherapy was under-
taken (P = 0.005).
Discussion
The best chance of survival for a patient with adrenocortical
carcinoma is when a complete tumour resection can be per-
formed. Although excision of metastases could not cure our
patients, we feel that debulking of tumour mass must be
maximised since chemotherapy is considered to be more
effective when tumour load is low (Harris & Mastrangelo,
1991).
In our series, more than half of the patients with a seem-
ingly complete tumour resection died of their disease within 5
years of surgery. It has been reported that local recurrence or
metastases occur in 80% of the patients after radical surgery
(Lipsett et al., 1963; Bertagna & Orth, 1981). Spillage of
tumour during operation may be the cause of tumour recur-
rence. However, in our series, rupture of the tumour capsule
during surgery was not associated with shorter survival.
Our findings suggest a significant favourable effect of mito-
tane treatment on patient survival in adrenocortical car-
cinoma. Other authors have previously suggested a similar
favourable effect (Hutter & Kayhoe, 1966b; Lubitz et al.,
1973; Venkatesh et al., 1989), but to our knowledge this has
never been well documented. Moreover, in a large retrospec-
tive study Luton et al. (1990) could not find an independent
beneficial effect resulting from mitotane therapy. Apart from
the effectiveness of mitotane treatment, there are no major
differences between our study and that of Luton et al. The
discrepancy in findings between the two studies may lie in the
different dosages of the drug used (or serum concentrations
reached), as was suggested by van Slooten et al. in 1984
(Haak et al., 1990). In the present study, an objective tumour
response, according to the strict WHO criteria, was found in
15 of the 27 evaluable patients with levels above 14 mg1'.
Continuous serum levels under 14 mg l' resulted in no
tumour response, and was tantamount to not giving mitotane
at all.
The differential effect of sex on patient survival observed in
our series is difficult to explain. The longer survival observed
in patients who received other chemotherapy cannot be
explained by objective tumour responses. It is possible that
chemotherapy retarded tumour progression in our patients,
resulting in a better survival. However, a bias may well have
occurred in selecting patients for treatment with
chemotherapy.
Despite all possible reservations against a retrospective
study, we feel that our results prove the efficacy of mitotane
in adrenocortical carcinoma. We have also clearly shown that
a patient with adrenocortical carcinoma may only benefit
from mitotane therapy when high serum levels of the drug
can be reached.
An important reason for not reaching therapeutic levels
may be undertreatment with steroids, resulting in signs and
symptoms of adrenocortical insufficiency. Because of in-
creased serum steroid-binding capacity during mitotaneADRENOCORTICAL CANCER AND MITOTANE TREATMENT 951
therapy, gluco- and mineralocorticoids must be supplied in
higher than normal amounts (van Seters & Moolenaar,
1991). A physician not aware of this will be more easily
inclined to lower mitotane dosage or even to stop the drug.
Of course, primary resistance of the tumour to mitotane and
rapid progression of the disease may be a major factor in
failure of the therapy.
Adjuvant mitotane therapy has been advocated after com-
plete tumour resection (Venkatesh et al., 1989; Luton et al.,
1990). In our study, patients who were treated adjuvantly
with mitotane did not do better than those who did not
receive it. On theoretical grounds, it is advisable to treat
patients with an active drug when tumour load is low (Harris
& Mastrangelo, 1991). More than half of the patients
develop recurrent disease after total tumour resection and
must thus have residual tumour tissue. Since recurrence can-
not be predicted, we feel that adjuvant therapy must be
considered in all patients after total tumour resection. How-
ever, the majority of patients will not benefit from this
treatment, for example when the carcinoma has been
confidently completely resected, or when the carcinoma is
unresponsive to mitotane. As the treatment is a burden to
most patients, we would not advocate adjuvant mitotane
treatment in patients with adrenocortical carcinoma after
complete tumour resection.
We conclude that surgery offers the best hope for long-
term survival for patients with adrenocortical carcinoma.
Mitotane treatment for patients with inoperable, recurrent,
and/or metastatic adrenocortical carcinoma is effective, pro-
vided that serum levels of the drug are maintained above
14mgl1'.
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N.A.T. Hamdy and Professor Dr F.J. Cleton for critical review of
the manuscript.
References
BECKER, D. & SCHUMACHER, O.P. (1975). O,p'DDD therapy in
invasive adrenocortical carcinoma. Ann. Intern. Med., 82,
677-679.
BERTAGNA, C. & ORTH, D.N. (1981). Clinical and laboratory
findings and results of therapy in 58 patients with adrenocortical
tumors admitted to a single medical center (1951 to 1978). Am. J.
Med., 71, 855-875.
ERIKSON, B., OBERG, K., CURSTEDT, T., HEMMINGSSON, A.,
JOHANSSON, H., LINDH, E., LINDGREN, P.G., THUOMAS, K.A.,
WILANDER, E. & AKERSTROM, G. (1987). Treatment of hor-
mone producing adrenocortical cancer with o,p'DDD and strep-
tozotocin. Cancer, 58, 1398-1403.
HAAK, H.R., VAN SETERS, A.P. & MOOLENAAR, A.J. (1990).
Mitotane therapy of adrenocortical carcinoma. N. Engl. J. Med.,
323, 758.
HARRIS, D.T. & MASTRANGELO, M.J. (1991). Theory and applica-
tion of early systemic therapy. Semin. Oncol., 493-503.
HUTTER, Jr, A.M. & KAYHOE, D.E. (1966a). Adrenal cortical car-
cinoma: clinical features of 138 patients. Am. J. Med., 41,
572-580.
HUTTER, A.M. & KAYHOE, D.E. (1966b). Adrenal cortical car-
cinoma: results of treatment with o,p'DDD in 138 patients. Am.
J. Med., 41, 581-592.
JARABAK, J. & RICE, K. (1981). Metastatic adrenal cortical car-
cinoma: prolonged regression with mitotane therapy. JAMA, 246,
1706-1707.
JOHNSON, D.H. & GRECO, F.A. (1986). Treatment of metastatic
adrenal cortical carcinoma with cisplatin and etoposide (VP-16).
Cancer, 58, 2198-2202.
LIPSETT, M.B., HERTZ, R. & ROSS, G.T. (1963). Clinical and
pathophysiologic aspects of adrenocortical carcinoma. Am. J.
Med., 35, 374-383.
LUBITZ, J.A., FREEMAN, L. & OKUN, R. (1973). Mitotane use in
inoperable adrenal cortical carcinoma. JAMA, 223,
1109-1112.
LUTON, J.P., CERDAS, S., BILLAUD, L., THOMAS, G., GUILHAUME,
B., BERTAGNA, X., LAUDAT, M.H., LOUVEL, A., CHAPUIS, Y.,
BLONDEAU, PH., BONNIN, A. & BRICAIRE, H. (1990). Clinical
features of adrenocortical carcinoma, prognostic factors, and the
effect of mitotane therapy. N. Engi. J. Med., 322, 1195-1201.
MACFARLANCE, D.A. (1958). Cancer of the adrenal cortex: the
natural history, prognosis and treatment in a study of fifty-five
cases. Ann. R. Coll. Surg. Engl., 23, 155-186.
MATHEWS, D.E. & FAREWELL, V. (1985). Using and Understanding
Medical Statistics. Karger: Basle.
MOOLENAAR, A.J., NIEWINT, J.W.M. & OEI, I.T. (1977). Estimation
of o,p'-DDD in plasma by gas-liquid chromatography. Clin.
Chim. Acta., 76, 213-218.
MOOLENAAR, A.J., VAN SLOOTEN, H., VAN SETERS, A.P. & SMEENK,
D. (1981). Blood levels of o,p'-DDD following administration in
various vehicles after a single dose and during long-term treat-
ment. Cancer Chemother. Pharmacol., 7, 51-54.
SAMAAN, N.A. & HICKEY, R.C. (1987). Adrenal cortical carcinoma.
Semin. Oncol., 14, 292-296.
VAN SETERS, A.P. & MOOLENAAR, A.J. (1991). Mitotane increases
the blood level of hormone-binding proteins. Acta Endocrinol.,
124, 526-533.
VAN SLOOTEN, H. & OOSTEROM, A.T. (1983). CAP (cyclophos-
phamide, doxorubicin, and cisplatin) regimen in adrenal cortical
carcinoma. Cancer Treat. Rep., 67, 377-379.
VAN SLOOTEN, H., MOOLENAAR, A.J., VAN SETERS, A.P. & SMEENK,
D. (1984). The treatment of adrenocortical carcinoma with o,p'-
DDD: prognostic implications of serum level monitoring. Eur. J.
Clin. Oncol., 20, 47-53.
VENKATESH, S., HICKEY, R.C., SELLIN, R.V., FERNANDEZ, J.F.,
SAMAAN, N.A. (1989). Adrenal cortical carcinoma. Cancer, 64,
765-769.